You are here

2-year follow-up from a randomized phase 3 trial (DASISION)

Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

8em; font-weight: bold; line-height: inherit; text-align: left; ">Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

  • Hagop M Kantarjian1,*, 
  • Neil P Shah2, 
  • Jorge E Cortes1,
  • Michele Baccarani3, 
  • Mohan B Agarwal4, 
  • María Soledad Undurraga5,
  • Jianxiang Wang6.........
  •  

  • Abstract

    Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n=259) or imatinib 400 mg (n=260) once daily. Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary endpoint), and major molecular response (MMR)......more

    http://bloodjournal.hematologylibrary.org/content/early/2011/12/09/blood-2011-08-376087.abstract